Benign uterine disease: Leiomyomata and benign polyps

The Endometrium: Molecular, Cellular and Clinical Perspectives, Second Edition

Volumn , Issue , 2008, Pages 797-812

  Maguire, Marcy ^a   Segars, James H ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042101316     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Ligon AH, Morton CC. Genetics of uterine leiomyomas. Genes Chromosomes Cancer 2000; 28: 235-45.
2. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308: 1589-92.
3. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003; 111: 1037-54.
4. Davis BJ. The NIEHS Uterine Fibroid Study: preliminary results. Presented at: Advances in Leiomyoma Research: 2nd NIH International Congress, Bethesda, MD, February 24-25, 2005.
5. Bajekal N, Li TC. Fibroids, infertility and pregnancy wastage. Hum Reprod Update 2000; 6: 614-20.
6. Payson M, Leppert P, Segars J. Epidemiology of myomas. Obstet Gynecol Clin North Am 2006; 33: 1-11.
7. Stewart EA, Morton CC. The genetics of leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107: 917-21.
8. Baird DD, Dunson DB, Hill MC et al. High cumulative incidence of uterine leiomyoma in black and white women. Am J Obstet Gynecol 2003; 188: 100-7.
9. Feinberg EC, Larsen FW, Catherino WH et al. Comparison of assisted reproductive technology utilization and outcomes between Caucasian and African American patients in an equal-access-to-care setting. Fertil Steril 2006; 85: 888-94.
10. Roth TM, Gustilo-Ashby T, Barber MD et al. Effects of race and clinical factors on short-term outcomes of abdominal myomectomy. Obstet Gynecol 2003; 101: 881-4.
11. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435-8.
12. Ryan GL, Syrop CH, Van Voorhis BJ. Role, epidemiology, and natural history of benign uterine mass lesions. Clin Obstet Gynecol 2005; 48: 312-24.
13. Patterson-Keels LM, Selvaggi SM, Haefner HK et al. Morphologic assessment of endometrium overlying submucosal leiomyomas. J Reprod Med 1994; 39: 579-84.
14. Deligdish L, Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol 1970; 23: 676-80.
15. Sharma SP, Misra SD, Mittal VP. Endometrial changes - a criterion for the diagnosis of submucous uterine leiomyoma. Indian J Pathol Microbiol 1979; 22: 33-6.
16. Sehgal N, Haskins AL. The mechanism of uterine bleeding in the presence of fibromyomas. Am Surg 1960; 26: 21-3.
17. Farrer-Brown G, Beilby JO, Tarbit MH. The vascular patterns in myomatous uteri. J Obstet Gynaecol Bronw Comm 1970; 77: 967-75.
18. Farrer-Brown G, Beilby JO, Tarbit MH. Venous changes in the endometrium of myomatous uteri. Obstet Gynecol 1971; 38: 743-51.
19. Huang SC, Yu CH, Huang RT et al. Intratumoral blood flow in uterine myoma correlated with a lower tumor size and volume, but not correlated with cell proliferation or angiogenesis. Obstet Gynecol 1996; 87: 1019-24.
20. Casey R, Rogers PAW, Vollenhoven BJ. An immunohistochemical analysis of fibroid vasculature. Hum Reprod 2000; 15: 1469-75.
21. Kurjak A, Kupesic-Urek S, Miric D. The assessment of benign uterine tumor vascularization by transvaginal color Doppler. Ultrasound Med Biol 1992; 18: 645-9.
22. Bulun SE, Simpson ER, Word RA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human leiomyoma tissues and cells in culture. J Clin Endocrinol Metab 1994; 78: 736-43.
23. Bulun SE, Imir G, Utsunomiya H et al. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol 2005; 95: 57-62.
24. Rackow BW, Taylor HS. Uterine leiomyomas affect molecular determinants of endometrial receptivity. Fertil Steril 2006; 86: S10.
25. Benson GV, Lim H, Paria BC et al. Mechanisms of reduced fertility in Hoxa-10 mutant mice: uterine homeosis and loss of maternal Hoxa-10 expression. Development 1996; 122: 2687-96.
26. Ingber DE. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 2002; 91: 877-87.
27. Paszek MJ, Weaver VM. The tension mounts: mechanics meets morphogenesis and malignancy. J Mammary Gland Biol Neoplasia 2004; 9: 325-42.
28. Huang S, Ingber DE. Cell tension, matrix mechanics, and cancer development. Cancer Cell 2005; 8: 175-6.
29. Sozen K, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the biology of uterine leiomyomata. Fertil Steril 2002; 78: 1-12.
30. Catherino WH, Leppert PC, Stenmark MH et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 2004; 40: 204-17.
31. Leppert PC, Baginski T, Prupas C et al. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril 2004; 82: 1182-7.
32. Cox DA, Helvering LM. Extracellular matrix integrity: a possible mechanism for differential clinical effects among selective estrogen receptor modulators and estrogens? Mol Cell Endocrinol 2006; 247: 53-9.
33. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyoma: a population-based study. Obstet Gynecol 2000; 95: 764-9.
34. Spies JB, Myers ER, Worthington-Kirsch R et al. The FIBROID registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol 2005; 106: 1309-18.
35. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest 2005; 59: 29-35.
36. Steinauer J, Pritts EA, Jackson R et al. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004; 103: 1331-6.
37. DeManno D, Elger W, Garg R et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003; 68: 1019-32.
38. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998; 83: 219-23.
39. Stewart EA, Disalvo D, Sharif NA et al. Pirendione for the treatment of uterine leiomyomas: pilot study data. J Soc Gynecol Invest 1999; 6: 229A.
40. Pritts EA. Fibroids and infertility: a systematic review of the evidence. Obstet Gynecol Surv 2001; 56: 483-91.
41. Gupta JK, Sinha AS, Lumsden MA et al. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev 2006; CD005073.
42. Pron G, Mocarski E, Bennett J et al. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol 2005; 105: 67-76.
43. Stewart EA, Rabinovici J, Tempany CM et al. Clinical outcomes of focused ultrasound surgery for the treatment of uterine fibroids. Fertil Steril 2006; 85: 22-9.
44. Nass Duce M, Oz U, Ozer C et al. Diagnostic value of sonohysterography in the evaluation of submucosal fibroids and endometrial polyps. Aust NZ J Obstet Gynaecol 2003; 43: 448-52.
45. Imaoka I, Sugimura K, Masui T et al. Abnormal uterine cavity: differential diagnosis with MR imaging. Mag Reson Imaging 1999; 17: 1445-55.
46. DeWaay DJ, Syrop CH, Nygaard IE et al. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002; 100: 3-7.
47. Van Bogaert L-J. Clinicopathologic findings in endometrial polyps. Obstet Gynecol 1988; 71: 771-3.
48. Maia H, Maltez A, Calmon LC et al. Histopathology and steroid receptors in endometrial polyps of postmenopausal patients under hormone replacement therapy. Gynaecol Endosc 1998; 7: 267-72.
49. McGurgan P, Taylor LJ, Duffy SR et al. Are endometrial polyps from premenopausal women similar to postmenopausal women? An immunohistochemical comparison of endometrial polyps from pre- and postmenopausal women. Maturitas 2006; 54: 277-84.
50. Mittal K, Schwartz L, Goswami S et al. Estrogen and progesterone receptor expression in endometrial polyps. Int J Gynecol Pathol 1996; 15: 345-8.
51. Savelli L, De Iaco P, Santini D et al. Histopathologic features and risks factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol 2003; 188: 927-31.
52. Sherman ME, Mazur MT, Kurman RJ. Benign diseases of the endometrium. In: Kurman RJ, ed. Blaustein’s Pathology of the Female Genital Tract. New York: Springer, 2002: 421-66.
53. Reslova T, Tosner J, Resl M et al. Endometrial polyps. Arch Gynecol Obstet 1999; 262: 133-9.
54. Dal-Cin P, Vanni R, Marras S et al. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res 1995; 55: 1565-8.
55. Hennig Y, Wanschura S, Diechert U et al. Rearrangements of the high mobility group protein family genes and the molecular genetic origin of uterine leiomyomas and endometrial polyps. Mol Hum Reprod 1996; 2: 277-83.
56. Taylor LJ, Jackson TL, Reid JG et al. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2, and Ki67 in endometrial polyps. BJOG 2003; 100: 794-8.
57. Sant’Ana de Almeida EC, Nogueira AA, Candido dos Reis FJ et al. Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps and adjacent endometrium in postmenopausal women. Maturitas 2004; 49: 229-33.
58. Arends MJ. Apoptosis in the endometrium. Histopathology 1999; 35: 174-8.
59. Maia H, Maltez A, Studart E et al. Ki-67, Bcl-2 and p53 expression in endometrial polyps and in the normal endometrium during the menstrual cycle. BJOG 2004; 111: 1242-7.
60. Maia H, Corriea T, Freitas LA et al. Cyclooxygenase-2 expression in endometrial polyps during menopause. Gynecol Endocrinol 2005; 21: 336-9.
61. Risberg B, Karlsson K, Abeler V et al. Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications. Int J Gynecol Pathol 2002; 21: 155-60.
62. Maia H, Maltez A, Athayde C et al. Proliferation profile of endometrial polyps in post-menopausal women. Maturitas 2001; 40: 273-81.
63. Mylonas I, Makovitzky J, Fernow A et al. Expression of the inhibin/activin subunits alpha (α) and beta-A(βA) and beta-B (βB) in benign human endometrial polyps and tamoxifenassociated polyps. Arch Gynecol Obstet 2005; 272: 59-66.
64. Smadar S, Arber N. Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side. Oncology 2005; 69: 33-7.
65. Hsu SC, Long C-Y, Yang C-H et al. Cycolooxygenase-2 expression in the endometrium at the end of two years’ continuous combined hormone replacement therapy. Maturitas 2003; 46: 295-9.
66. Fujiwaki R, Iida K, Kanasaki H et al. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002; 33: 213-9.
67. Ferrandina G, Legge F, Ranelletti FO et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002; 95: 801-7.
68. Anastasiadis PG, Koutlaki NG, Skaphida PG et al. Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 2000; 21: 180-3.
69. Shushan A, Revel A, Rojansky N. How often are endometrial polyps malignant? Gynecol Obstet Invest 2004; 58: 212-15.
70. Farrell R, Scurry J, Otton G et al. Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium. Gynecol Oncol 2005; 98: 254-62.
71. Peterson WF, Novak ER. Endometrial polyps. Obstet Gynecol 1956; 8: 40-9.
72. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990; 3: 120-8.
73. McCluggage WG, Sumathi VP, McManus DT. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising from endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol 2003; 34: 939-43.
74. Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 1996; 56: 1917-21.
75. Pickartz H, Beckmann R, Fleige B et al. Steroid receptors and proliferative activity in non-neoplastic and neoplastic endometria. Virchows Arch A Pathol Anat Histopathol 1990; 417: 163-71.
76. Li SF, Shiozawa T, Nakayama K et al. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid adenocarcinoma. Cancer 1996; 77: 321-9.
77. Niemann TH, Trgovac TL, McGaughty VR et al. Bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 1996; 63: 318-22.
78. Belisario MS, Vassallo J, Andrade LA et al. The expression of hormone receptors in the endometrium and endometrial polyps in postmenopausal women and its relationship to body mass index. Maturitas 2006; 53: 114-18.
79. Bakour SH, Gupta JK, Khan KS. Risk factors associated with endometrial polyps in abnormal uterine bleeding. Int J Gynecol Obstet 2002; 76: 165-8.
80. Fong K, Kung R, Lytwyn A et al. Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Radiology 2001; 220: 765-73.
81. Mourits MJ, Ten Hoor KA, van der Zee AGJ et al. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 2002; 55: 514-19.
82. Neven P, Quail D, Lévrier M et al. Uterine effects of Estrogen Plus Progestin Therapy and Raloxifene: Adjudicated Results From the EURALOX Study. Obstet Gynecol 2004; 103: 881-91.
83. Gardner FJ, Konje JC, Abrams KR et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356: 1711-17.
84. Oguz S, Sargin A, Kelekci S et al. The role of hormone replacement therapy in endometrial polyp formation. Maturitas 2005; 50: 231-6.
85. Van den Bosch T, Van Schoubroeck D, Ameye L et al. Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormone replacement therapy. Am J Obstet Gynecol 2003; 188: 1249-53.
86. Perrone G, DeAngelis C, Critelli C et al. Hysteroscopic findings in postmenopausal abnormal uterine bleeding: a comparison between HRT users and non-users. Maturitas 2002; 43: 251-5.
87. Kim MR, Kim YA, Jo MY et al. High frequency of endometrial polyps in endometriosis. J Am Asso Gynecol Laparosc 2003; 10: 46-8.
88. Tjarks M, Van Voorhis BJ. Treatment of endometrial polyps. Obstet Gynecol 2000; 96: 886-9.
89. Cohen MA, Sauer MV, Ketz M. Utilizing routine sonohysterography to detect intrauterine pathology before initiating hormone replacement therapy. Menopause 1999; 6: 68-70.
90. Fabres C, Alam V, Balmaceda J et al. Comparison of ultrasonography and hysteroscopy in the diagnosis of intrauterine lesions in infertile women. J Am Assoc Gynecol Laparosc 1998; 5: 375-8.
91. La Torre R, De Felice C, De Angelis C et al. Transvaginal sonographic evaluation of endometrial polyps: a comparison of two-dimensional and three-dimensional contrast sonography. Clin Exp Obstet Gynecol 1999; 26: 171-3.
92. Pérez-Medina T, Bajo-Arenas J, Salazar F et al. Endometrial polyps and their implication in the pregnancy rates of patients undergoing intrauterine insemination: a prospective, randomized study. Hum Reprod 2005; 20: 1632-5.
93. Davis PC, O’Neill MJ, Yoder IC et al. Sonohysterographic findings of endometrial and subendometrial conditions. Radiographics 2002; 22: 803-16.
94. Soares SR, Barbosa dos Reis MB, Camargos AF. Diagnostic accuracy of sonohysterography, transvaginal sonography, and hysterosalpingography in patients with uterine cavity diseases. Fertil Steril 2000; 73: 406-11.
95. Fong K, Causer P, Atri M et al. Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. Radiographics 2003; 23: 137-55.
96. Davidson KG, Dubinsky TJ. Ultrasonographic evaluation of the endometrium in postmenopausal vaginal bleeding. Radiol Clin North Am 2003; 41: 769-80.
97. Hann LE, Kim CM, Gonen M et al. Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. J Ultrasound Med 2003; 22: 1173-9.
98. Chaudhry S, Reinhold C, Guermazi A et al. Benign and malignant disorders of the endometrium. Top Magn Reson Imaging 2003; 14: 339-58.
99. Cravello L, de Montgolfier R, D’Ercole C et al. Hysteroscopic surgery in postmenopausal women. Acta Obstet Gynecol Scand 1996; 75: 536-6.
100. Gebauer G, Hafner A, Siebzehnrübl E et al. Role of hysteroscopy in detection and extraction of endometrial polyps: results of a prospective study. Am J Obstet Gynecol 2001; 184: 59-63.